PanThera Bio

Executive Summary

PanThera Bio is a private UK-based oncology and immunology company advancing innovative therapies through clinical trials. Founded in 2018, the company focuses on providing early access to potential new treatments for patients, with the goal of improving care and expanding medical knowledge. Currently in Phase 3 development, PanThera Bio is positioned to address significant unmet needs in cancer and immune-related conditions. The company's strategy emphasizes accelerated development pathways and patient access, leveraging its clinical trial platform to generate compelling efficacy and safety data. With a lean structure and a clear focus on late-stage assets, PanThera Bio is poised for potential value inflection as it approaches key regulatory and clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data Readout60% success
• Q4 2026Regulatory Submission (EMA/MHRA)50% success
• TBDStrategic Partnership or Licensing Deal40% success